CLPBF (Coloplast AS) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPBF Coloplast AS CLPBF
72 GF Score
Price $61.76
GF Value $126.14
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS SpecialCharges?

Special Charges only applies to banks.

CLPBF
72GF Score
Coloplast AS CLPBF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coloplast AS (CLPBF) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $61.76 is trading 51% below its estimated GF Value™ of $126.14. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBF:

  • SpecialCharges:
  • GF Value™: $126.14 vs. price of $61.76 (51% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score

Get the complete analysis for CLPBF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.76
Price
$126.14
GF Value